UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 9)
Greenbrook
TMS Inc.
(Name of Issuer)
Common
Shares, no par value
(Title of Class of Securities)
393704309
(CUSIP Number)
Sasha
Cucuz
Greybrook
Health Inc.
890
Yonge Street, 7th Floor
Toronto,
Ontario M4W 3P4
(647) 478-8881
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 25, 2024
(Date of Event Which Requires Filing of This
Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of
the Act.
CUSIP No. 393704309
1 |
|
NAMES OF REPORTING PERSONS
GREYBROOK HEALTH INC.
|
2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x – Joint Filing
|
3 |
|
SEC USE ONLY
|
4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS)
OO
|
5 |
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(D) OR 2(E)
¨ |
6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION
ONTARIO
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
|
7 |
|
SOLE VOTING POWER
0
|
|
8 |
|
SHARED VOTING POWER
45,716,901(1)
|
|
9 |
|
SOLE DISPOSITIVE POWER
0
|
|
10 |
|
SHARED DISPOSITIVE POWER
45,716,901(1)
|
11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
45,716,901(1)
|
12 |
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
¨
|
13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
54.2%(2)
|
14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) This amount includes (i) 6,800,424
common shares, no par value (the “Common Shares”), of Greenbrook TMS Inc. (the “Issuer”) beneficially
owned by Greybrook Health Inc. (“Greybrook Health”) and 200,000 Common Shares directly owned by Greybrook Realty, an
affiliate of Greybrook Health and an indirect subsidiary of the Trust (as defined below), (ii) 385,870 Common Shares issuable to
Greybrook Health upon the exercise of common share purchase warrants of the Issuer (the “Warrants”) and (iii) an
aggregate of 38,330,607 Common Shares estimated to be issuable to Greybrook Health upon conversion of up to US$3,844,559.88 of subordinated
convertible promissory notes (the “Subordinated Convertible Notes”).
(2) This percentage is calculated based upon
45,602,260 outstanding Common Shares of the Issuer as of May 3, 2024 as reported in the Issuer’s Proxy Statement filed with the
Securities and Exchange Commission (“SEC”) on May 10, 2024, plus an additional (i) 385,870 Common Shares issuable
to Greybrook Health upon the exercise of the Warrants and (ii) an aggregate of 38,330,607 Common Shares estimated to be issuable
to Greybrook Health upon conversion of the Subordinated Convertible Notes.
CUSIP No. 393704309
1 |
|
NAMES OF REPORTING PERSONS
THE VAMVAKAS FAMILY TRUST (2015)
|
2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x – Joint Filing
|
3 |
|
SEC USE ONLY
|
4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS)
OO
|
5 |
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(D) OR 2(E)
¨ |
6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION
ONTARIO
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
|
7 |
|
SOLE VOTING POWER
0
|
|
8 |
|
SHARED VOTING POWER
45,716,901(1)
|
|
9 |
|
SOLE DISPOSITIVE POWER
0
|
|
10 |
|
SHARED DISPOSITIVE POWER
45,716,901(1)
|
11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
45,716,901(1)
|
12 |
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
¨
|
13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
54.2%(2)
|
14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
OO
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Reflects deemed shared beneficial ownership
with Greybrook Health, the indirect subsidiary of The Vamvakas Family Trust (2015), as reported above.
(2) See note 2 for Greybrook Health, as reported
above.
EXPLANATORY NOTE
This ninth amendment (this “Amendment
No. 9”) to the original Schedule 13D previously filed on May 9, 2023 (the “Original Schedule 13D”) is being
filed by and on behalf of Greybrook Health, a corporation formed under the laws of the Province of Ontario, Canada, and The Vamvakas Family
Trust (2015), a trust formed under the laws of the Province of Ontario, Canada (the “Trust,” and together with Greybrook
Health, the “Reporting Persons”), to reflect the increase in the beneficial ownership of Common Shares by the Reporting
Persons resulting from a decrease in the conversion price of the Subordinated Convertible Notes that are held by Greybrook Health. The
Original Schedule 13D, as previously amended, is herein referred to as the “Existing Schedule 13D”. The Existing Schedule
13D, as amended by this Amendment No. 9, is herein referred to as this “Schedule 13D”.
Information and defined terms reported in the
Existing Schedule 13D remains in effect except to the extent that it is amended or superseded by information or defined terms contained
in this Amendment No. 9.
Item 2. Identity and Background.
Subordinated Convertible Notes
As of June 26, 2024, the Reporting Persons are
deemed to beneficially own an aggregate of 38,330,607 Common Shares estimated to be issuable upon conversion of the US$3,267,876 principal
amount of Subordinated Convertible Notes held by Greybrook Health. In accordance with the definition of “Conversion Price”
in the Subordinated Note Purchase Agreement, Greybrook Health is entitled to a conversion price equal to 85% of the 30-Day VWAP immediately
prior to the date of the applicable exercise of conversion rights; provided, that, in any event, the conversion price shall not be lower
than $0.078 (as adjusted for any subdivision, combination or stock dividend) (the “Floor Price”). The 30-Day VWAP has
been calculated to reflect the trading price of the Common Shares on OTCQB and accordingly, as of June 26, 2024, was $0.1003, 85% of which
is equal to $0.0853 (the “Updated Conversion Price”), which is lower than the previously reported conversion price
of $0.0892 (the “Previously Reported Conversion Price”) and accordingly the Updated Conversion Price replaces the Previously
Reported Conversion Price as the applicable conversion price under the Subordinated Note Purchase Agreement. The conversion price of the
Subordinated Convertible Notes will continue to increase and decrease alongside the Company’s 30-Day VWAP as per the definition
of “Conversion Price” in the Subordinated Note Purchase Agreement. The decrease of the conversion price to the Updated Conversion
Price from the Previously Reported Conversion Price and the convertible interest accruing on the Subordinated Convertible Notes held by
Greybrook Health has increased the number of Common Shares into which the Subordinated Convertibles Notes are convertible by 1,904,701,
resulting in the Reporting Persons beneficially owning 54.2% of the Common Shares as of June 26, 2024.
Item 5. Interest in Securities of the Issuer.
Item 5(a)-(c) of the Existing Schedule 13D
is hereby supplemented as follows:
(a)-(b) The aggregate number and percentage of
Common Shares beneficially owned by the Reporting Persons to which this Schedule 13D relates is 45,716,901 Common Shares, constituting
approximately 54.2% of the Issuer’s outstanding Common Shares, and including (i) 6,800,424 Common Shares that are directly owned
by Greybrook Health and 200,000 Common Shares directly owned by Greybrook Realty, an affiliate of Greybrook Health and an indirect subsidiary
of the Trust, (ii) 385,870 Common Shares issuable to Greybrook Health upon exercise of the Warrants and (iii) an aggregate of 38,330,607
Common Shares estimated to be issuable to Greybrook Health upon conversion of the Subordinated Convertible Notes. The percentage of Common
Shares of the Issuer is calculated based upon 45,602,260 outstanding Common Shares of the Issuer as of May 3, 2024 as reported in the
Issuer’s Proxy Statement filed with the SEC on May 10, 2024, plus an additional (i) 385,870 Common Shares issuable to Greybrook
Health upon the exercise of the Warrants and (ii) an aggregate of 38,330,607 Common Shares estimated to be issuable to Greybrook Health
upon conversion of the Subordinated Convertible Notes.
(c) Other than the transactions described herein,
there have been no other transactions by the Reporting Persons in the Common Shares during the past 60 days.
Item 6. Contracts, Arrangements, Understandings or Relationships
with Respect to Securities of the Issuer.
The information set forth in Item 2 of this Amendment
No. 9 is hereby incorporated by reference into Item 6 of the Existing Schedule 13D.
SIGNATURES
After reasonable inquiry and
to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete
and correct.
June 27, 2024 |
|
|
GREYBROOK HEALTH INC. |
|
|
|
By: |
/s/ Sasha Cucuz |
|
|
Name: |
Sasha
Cucuz
|
|
|
Title: |
Director |
|
|
|
|
THE VAMVAKAS FAMILY TRUST (2015) |
|
|
|
By: |
/s/ Sasha Cucuz |
|
|
Name: |
Sasha
Cucuz
|
|
|
Title: |
Trustee |
|
|
|
|
By: |
/s/ Shawn Walsh |
|
|
Name: |
Shawn
Walsh
|
|
|
Title: |
Trustee |
Greenbrook TMS (NASDAQ:GBNH)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Greenbrook TMS (NASDAQ:GBNH)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024